These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28737131)

  • 1. Pharmacokinetics of flucloxacillin and its metabolites in patients with renal failure: Impact on liver toxicity
.
    Maier-Salamon A; Elgendy SA; Meyer B; Vossen M; Thalhammer T; Thalhammer F; Jäger W
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):701-711. PubMed ID: 28737131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin.
    Meyer B; Ahmed el Gendy S; Delle Karth G; Locker GJ; Heinz G; Jaeger W; Thalhammer F
    Kidney Blood Press Res; 2003; 26(2):135-40. PubMed ID: 12771540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients.
    Gath J; Charles B; Sampson J; Smithurst B
    J Clin Pharmacol; 1995 Jan; 35(1):31-6. PubMed ID: 7751411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes.
    Lakehal F; Dansette PM; Becquemont L; Lasnier E; Delelo R; Balladur P; Poupon R; Beaune PH; Housset C
    Chem Res Toxicol; 2001 Jun; 14(6):694-701. PubMed ID: 11409940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats.
    Carey MA; van Pelt FN
    Toxicology; 2005 Dec; 216(1):41-8. PubMed ID: 16112790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and distribution of flucloxacillin in pacemaker patients.
    Anderson P; Bluhm G; Ehrnebo M; Herngren L; Jacobson B
    Eur J Clin Pharmacol; 1985; 27(6):713-9. PubMed ID: 3987776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis.
    Nauta EH; Mattie H
    Br J Clin Pharmacol; 1975 Apr; 2(2):111-21. PubMed ID: 1234495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic disposition of flucloxacillin in patients with impaired kidney function.
    Thijssen HH; Wolters J
    Eur J Clin Pharmacol; 1982; 22(5):429-34. PubMed ID: 7117355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of free and total flucloxacillin in newborn infants.
    Herngren L; Ehrnebo M; Broberger U
    Eur J Clin Pharmacol; 1987; 32(4):403-9. PubMed ID: 3609118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.
    Pullen J; de Rozario L; Stolk LM; Degraeuwe PL; van Tiel FH; Zimmermann LJ
    Ther Drug Monit; 2006 Jun; 28(3):351-8. PubMed ID: 16778719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal impairment after high-dose flucloxacillin and single-dose gentamicin prophylaxis in patients undergoing elective hip and knee replacement.
    Challagundla SR; Knox D; Hawkins A; Hamilton D; W V Flynn R; Robertson S; Isles C
    Nephrol Dial Transplant; 2013 Mar; 28(3):612-9. PubMed ID: 23197677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
    Bastien O; Bolon M; Flamens C; Lehot JJ; Boulieu R
    Ann Fr Anesth Reanim; 2002 Nov; 21(9):692-7. PubMed ID: 12494801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man.
    Fox E; Cheng V; Rawlins M; Dyer J; De Keulenaer B; Page MM; Hoad K; Roberts JA
    J Chemother; 2019; 31(7-8):419-423. PubMed ID: 31650900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flucloxacillin-induced liver injury.
    Andrews E; Daly AK
    Toxicology; 2008 Dec; 254(3):158-63. PubMed ID: 18793693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701.
    Teixeira M; Macedo S; Batista T; Martins S; Correia A; Matos LC
    Rev Assoc Med Bras (1992); 2020; 66(1):12-17. PubMed ID: 32130375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and half-life of two preparations of flucloxacillin.
    Paton DM; Mander P; Avery RJ
    N Z Med J; 1982 Nov; 95(719):766-8. PubMed ID: 6959033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extremely high unbound flucloxacillin concentrations in a patient with acute septic renal failure during continuous venovenous hemofiltration: Therapeutic drug monitoring to optimize treatment.
    Appelman EM; Wammes van-der-Heijden EA; Meenks SD; Janssen PKC; le Noble JLML
    Int J Clin Pharmacol Ther; 2023 Mar; ():. PubMed ID: 36871242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.